Stocks TelegraphStocks Telegraph
Stock Ideas

ST Premium

Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Try Now for Just $1!

Zhongchao Inc. (ZCMD) stock Skyrockets Premarket After Plunging to New Low

By
Published On January 1, 1970 12:00 AM UTC
Zhongchao Inc. (ZCMD) stock Skyrockets Premarket After Plunging to New Low

On March 14, Zhongchao Inc. (ZCMD) stock skyrocketed in the premarket to add an immense 60.00%. Thus, at the time of writing, the stock was trading at a price of $1.68 per share in the premarket. The volume of the shares exchanged was 754.2K at the time. There is no recent official announcement or SEC filing from the company.

In the previous trading session on Friday, ZCMD fluctuated between $1.05 and $1.75 to report its new 52-week low of $1.05. The stock closed the session with a huge loss of 38.24% at a price of $1.05 per share.

The healthcare information, education, and training services provider, Zhongchao Inc. is based in China.

ZCMD’s Trend Reversal

As the stock markets continued to suffer from the frenzy caused by the Russia-Ukraine conflict, ZCMD shared a similar fate. With healthcare stocks taking a harsh hit, ZCMD had also been going down since March 08. Continuing the downfall, the stock plunged to its new 52-week low of $1.05 on Friday. Consequently, the stock rebounded in the premarket session today. Since there is no recent news from the company, it seems the new low gave way to the recovery today. It is most likely that investors saw the new low price of the stock as a good opportunity to stock up. Hence, the stock rebounded and surged up in the premarket today due to external factors.

It is unclear as to how long the current bullish momentum will continue as the market is highly volatile but for now, the stock is up for some good gains.

Company News

On October 29, the company announced updates regarding its self-developed patient management system. ZCMD’s patient management system improves the Duration of Therapy by 40.4% for patients with liver cancer. Therefore, contributing to maximum drugs efficiency, successful treatment, and extended patient survival terms.

Source: HarmoniMD

As per The Global Cancer Observatory, China had 400,000 new liver cancer cases in 2020. The main treatment of liver cancer currently includes surgical resection, interventional therapy, radiotherapy, and transplant. All these treatments have limitations specifically adverse reactions during the systemic therapies usually decrease life quality and negatively effects treatment. So, ZCMD closely monitors and deals with adverse reactions through its patient management system. Follow-up, psychological counseling, drugs usage reminder, and patient supervision all are done through the system.

On September 17, the company announced the launch of its multidisciplinary treatment (MDT) clinical thinking training platform for hematology. This platform provides a channel for learning multidisciplinary thinking skills online. Hence, improving diagnosis and treatment along with efficiency.

logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph